1. Pink Sheet

RSV Vaccine May Be On Market In 2023, CDC’s ACIP Anticipates

 
• By Brenda Sandburg

Panel expects to review five respiratory syncytial virus vaccines and vote on one or two of them in June 2023 and others four months later. Sanofi presents results of three clinical trials of its monoclonal antibody nirsevimab, which is on track to be the second RSV prophylaxis for infants.

Respiratory syncytial virus
CDC advisory committee plans to review five RSV vaccines in the next year • Source: Shutterstock

With several vaccines for prevention of respiratory syncytial virus in late-stage development, there is intense anticipation as to when the first one will gain approval. The US Centers of Disease Control and Prevention’s Advisory Committee on Immunization Practices indicated that this may happen by the middle of next year.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA Performance Tracker

More from Regulatory Trackers